A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors.
Mansfield AS, Hong DS, Hann CL, Farago AF, Beltran H, Waqar SN, Hendifar AE, Anthony LB, Taylor MH, Bryce AH, Tagawa ST, Lewis K, Niu J, Chung CH, Cleary JM, Rossi M, Ludwig C, Valenzuela R, Luo Y, Aggarwal R.
Mansfield AS, et al. Among authors: luo y.
NPJ Precis Oncol. 2021 Aug 5;5(1):74. doi: 10.1038/s41698-021-00214-y.
NPJ Precis Oncol. 2021.
PMID: 34354225
Free PMC article.